NCT05686174 is a Phase 1 clinical trial of MBS217 in Non-Alcoholic Fatty Liver Disease, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT05686174?

NCT05686174 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT05686174?

Interventions in NCT05686174: MBS217, Placebo.

What condition does NCT05686174 study?

NCT05686174 studies Non-Alcoholic Fatty Liver Disease.

Is NCT05686174 still recruiting?

NCT05686174 is currently status unknown. Last updated 17 January 2023.

Last reviewed 2023-01-17 · How we verify

NCT05686174

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation on Safety and Efficacy of Soybean Fermented Extract (MBS217) in Treating Patients With NAFLD

Status unknown Phase 1 Last updated 17 January 2023

What this trial tests

Phase 1 trial testing MBS217 in Non-Alcoholic Fatty Liver Disease in 30 participants. Status unknown.

Timeline

1 February 2023

Primary endpoint
30 April 2024

31 December 2024

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	1 February 2023
Primary completion	30 April 2024
Estimated completion	31 December 2024

Drugs / interventions tested

MBS217
Placebo

Conditions studied

Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 70, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators aimed to investigate the efficacy and safety of fermented soybean extract (MBS-217) in treating participants with Non-alcoholic fatty liver disease (NAFLD) in this study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma.
Ren S, Zhang Y, Wang X, Su J, et al · · 2025 · cited 5× · PMID 40070843 · DOI 10.3389/fimmu.2025.1526967

Verify or expand the search:

Other recruiting trials for Non-Alcoholic Fatty Liver Disease

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
NCT06863376 — Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients · Phase 2 · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05686174 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 17 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05686174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing